MedKoo Cat#: 562937 | Name: L-708906

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L-708906 is an inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1).

Chemical Structure

L-708906
L-708906
CAS#251963-74-3

Theoretical Analysis

MedKoo Cat#: 562937

Name: L-708906

CAS#: 251963-74-3

Chemical Formula: C24H20O6

Exact Mass: 404.1260

Molecular Weight: 404.41

Elemental Analysis: C, 71.28; H, 4.98; O, 23.74

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
L-708906; L 708906; L708906; ARRY142886; ARRY-142886; ARRY 142886;
IUPAC/Chemical Name
4-[3,5-Bis(phenylmethoxy)phenyl]-2,4-dioxobutanoic acid
InChi Key
SLRLQBRWUMWEOZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H20O6/c25-22(14-23(26)24(27)28)19-11-20(29-15-17-7-3-1-4-8-17)13-21(12-19)30-16-18-9-5-2-6-10-18/h1-13H,14-16H2,(H,27,28)
SMILES Code
O=C(O)C(CC(C1=CC(OCC2=CC=CC=C2)=CC(OCC3=CC=CC=C3)=C1)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 404.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Beare KD, Coster MJ, Rutledge PJ. Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond. Curr Med Chem. 2012;19(8):1177-92. Review. PubMed PMID: 22214459. 2: Barreca ML, Iraci N, De Luca L, Chimirri A. Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. ChemMedChem. 2009 Sep;4(9):1446-56. doi: 10.1002/cmdc.200900166. PubMed PMID: 19544345. 3: Chi G, Nair V, Semenova E, Pommier Y. A novel diketo phosphonic acid that exhibits specific, strand-transfer inhibition of HIV integrase and anti-HIV activity. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1266-9. Epub 2006 Dec 15. PubMed PMID: 17188872; PubMed Central PMCID: PMC1839884. 4: Johnson AA, Marchand C, Pommier Y. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Curr Top Med Chem. 2004;4(10):1059-77. Review. PubMed PMID: 15193139. 5: Fikkert V, Van Maele B, Vercammen J, Hantson A, Van Remoortel B, Michiels M, Gurnari C, Pannecouque C, De Maeyer M, Engelborghs Y, De Clercq E, Debyser Z, Witvrouw M. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol. 2003 Nov;77(21):11459-70. PubMed PMID: 14557631; PubMed Central PMCID: PMC229256. 6: Neamati N. Dipyrimidine-based inhibitors of HIV-1 integrase. Expert Opin Investig Drugs. 2003 Feb;12(2):289-92. Review. PubMed PMID: 12556222. 7: Pluymers W, Pais G, Van Maele B, Pannecouque C, Fikkert V, Burke TR Jr, De Clercq E, Witvrouw M, Neamati N, Debyser Z. Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives. Antimicrob Agents Chemother. 2002 Oct;46(10):3292-7. PubMed PMID: 12234864; PubMed Central PMCID: PMC128766. 8: Rao GS, Bhatnagar S, Ahuja V. Structure-based design of a novel peptide inhibitor of HIV-1 integrase: a computer modeling approach. J Biomol Struct Dyn. 2002 Aug;20(1):31-8. PubMed PMID: 12144350. 9: Pais GC, Zhang X, Marchand C, Neamati N, Cowansage K, Svarovskaia ES, Pathak VK, Tang Y, Nicklaus M, Pommier Y, Burke TR Jr. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J Med Chem. 2002 Jul 18;45(15):3184-94. PubMed PMID: 12109903. 10: Marchand C, Zhang X, Pais GC, Cowansage K, Neamati N, Burke TR Jr, Pommier Y. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem. 2002 Apr 12;277(15):12596-603. Epub 2002 Jan 22. PubMed PMID: 11805103. 11: Vandegraaff N, Kumar R, Hocking H, Burke TR Jr, Mills J, Rhodes D, Burrell CJ, Li P. Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother. 2001 Sep;45(9):2510-6. PubMed PMID: 11502522; PubMed Central PMCID: PMC90685. 12: Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000 Jan 28;287(5453):646-50. PubMed PMID: 10649997.